Presumably, this discrepancy results from the fact that BRCAPRO does not model any of the residual familial clustering of breast cancer, other than BRCA1 or BRCA2, so that individuals with moderate family histories are assigned probabilities for being mutation carriers that are too high. This evidence concerns the gene BRCA2 and breast carcinoma.